Referenser

  1. Nationellt system för kunskapsstyrning hälso- och sjukvård. Vårdförlopp och vårdprogram inflammatorisk tarmsjukdom (IBD) Stockholm: Sveriges regioner i samverkan; 2023 [Available from: https://kunskapsstyrningvard.se/kunskapsstyrningvard/kunskapsstod/publiceradekunskapsstod/magochtarmsjukdomar/vardforloppochvardprograminflammatorisktarmsjukdomibd.67275.html

  2. Forss A, Clements M, Bergman D, Roelstraete B, Kaplan GG, Myrelid P, et al. A nationwide cohort study of the incidence of inflammatory bowel disease in Sweden from 1990 to 2014. Aliment Pharmacol Ther. 2022;55(6):691-9.

  3. Büsch K, Ludvigsson JF, Ekström-Smedby K, Ekbom A, Askling J, Neovius M. Nationwide prevalence of inflammatory bowel disease in Sweden: a population-based register study. Aliment Pharmacol Ther. 2014;39(1):57-68.

  4. Chang JT. Pathophysiology of Inflammatory Bowel Diseases. N Engl J Med. 2020;383(27):2652-64.

  5. Parkes GC, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect. J Crohns Colitis. 2014;8(8):717-25.

  6. Salih A, Widbom L, Hultdin J, Karling P. Smoking is associated with risk for developing inflammatory bowel disease including late onset ulcerative colitis: a prospective study. Scand J Gastroenterol. 2018;53(2):173-8.

  7. Reese GE, Nanidis T, Borysiewicz C, Yamamoto T, Orchard T, Tekkis PP. The effect of smoking after surgery for Crohn’s disease: a meta-analysis of observational studies. International Journal of Colorectal Disease. 2008;23(12):1213-21.

  8. Bolckmans R, Kalman T, Singh S, Ratnatunga KC, Myrelid P, Travis S, et al. Does Smoking Cessation Reduce Surgical Recurrence After Primary Ileocolic Resection for Crohn's Disease? Dis Colon Rectum. 2020;63(2):200-6.

  9. Tibble JA, Sigthorsson G, Bridger S, Fagerhol MK, Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119(1):15-22.

  10. Nationellt system för kunskapsstyrning hälso- och sjukvård. Nationellt vårdprogram för vuxna med inflammatorisk tarmsjukdom (IBD): Sveriges regioner i samverkan; 2023 [Available from: https://d2flujgsl7escs.cloudfront.net/external/Nationellt-vardprogram-for-vuxna-med-inflammatorisk-tarmsjukdom-(IBD).pdf

  11. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55(6):749-53.

  12. Magro F, Cordeiro G, Dias AM, Estevinho MM. Inflammatory Bowel Disease - Non-biological treatment. Pharmacol Res. 2020;160:105075.

  13. Viscido A, Papi C, Latella G, Frieri G. Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? Biologics. 2019;13:23-31.

  14. Raine T, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. Journal of Crohn's and Colitis. 2021;16(1):2-17.

  15. Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis. 2019;14(1):4-22.

  16. de Boer NKH, Peyrin-Biroulet L, Jharap B, Sanderson JD, Meijer B, Atreya I, et al. Thiopurines in Inflammatory Bowel Disease: New Findings and Perspectives. J Crohns Colitis. 2018;12(5):610-20.

  17. Estevinho MM, Afonso J, Rosa I, Lago P, Trindade E, Correia L, et al. A Systematic Review and Meta-Analysis of 6-Thioguanine Nucleotide Levels and Clinical Remission in Inflammatory Bowel Disease. J Crohns Colitis. 2017;11(11):1381-92.

  18. Torres J, Chaparro M, Julsgaard M, Katsanos K, Zelinkova Z, Agrawal M, et al. European Crohn's and Colitis Guidelines on Sexuality, Fertility, Pregnancy, and Lactation. J Crohns Colitis. 2023;17(1):1-27.

  19. Johnson CM, Dassopoulos T. Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease. Curr Gastroenterol Rep. 2018;20(11):53.

  20. Holmgren J, Fröborg A, Visuri I, Halfvarson J, Hjortswang H, Karling P, et al. The Risk of Serious Infections Before and After Anti-TNF Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study. Inflamm Bowel Dis. 2023;29(3):339-48.

  21. Peyrin-Biroulet L, Arkkila P, Armuzzi A, Danese S, Guardiola J, Jahnsen J, et al. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis. BMC Gastroenterol. 2022;22(1):291.

  22. Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386(4):316-26.

  23. EMA. Janus kinase inhibitors (JAKi) - referral: Eurpean Medicines Agency; 2023 [Available from: https://www.ema.europa.eu/en/medicines/human/referrals/janus-kinase-inhibitors-jaki

  24. Läkemedelsverket. Behandlingsrekommendation: Läkemedelsbehandling vid inflammatorisk tarmsjukdom (IBD). Uppsala: Läkemedelsverket; 2021 [Available from: https://www.lakemedelsverket.se/sv/behandling-och-forskrivning/behandlingsrekommendationer/sok-behandlingsrekommendationer/lakemedel-vid-inflammatorisk-tarmsjukdom-ibd---behandlingsrekommendation

  25. Spinelli A, Bonovas S, Burisch J, Kucharzik T, Adamina M, Annese V, et al. ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. Journal of Crohn's and Colitis. 2021;16(2):179-89.

  26. Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, et al. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis. 2021;15(6):879-913.

  27. Gordon H, Biancone L, Fiorino G, Katsanos KH, Kopylov U, Al Sulais E, et al. ECCO Guidelines on Inflammatory Bowel Disease and Malignancies. J Crohns Colitis. 2023;17(6):827-54.

  28. Adamina M, Bonovas S, Raine T, Spinelli A, Warusavitarne J, Armuzzi A, et al. ECCO Guidelines on Therapeutics in Crohn’s Disease: Surgical Treatment. Journal of Crohn's and Colitis. 2019;14(2):155-68.

  29. Miehlke S, Guagnozzi D, Zabana Y, Tontini GE, Kanstrup Fiehn AM, Wildt S, et al. European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations. United European Gastroenterol J. 2021;9(1):13-37.

  30. Bergman D, Khalili H, Roelstraete B, Ludvigsson JF. Microscopic colitis and risk of cancer - a population-based cohort study. J Crohns Colitis. 2020.

Föregående sida
För vidare läsning

Nästa sida
Tillbaka till kapitlets första sida